Business Description
Egetis Therapeutics AB
NAICS : 325412
SIC : 2834
ISIN : SE0003815604
Compare
Compare
Traded in other countries / regions
EGTX.SwedenP0F.Germany IPO Date
2011-04-07Description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.68 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.67 | |||||
| Beneish M-Score | -1.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.3 | |||||
| 3-Year EBITDA Growth Rate | 20.2 | |||||
| 3-Year EPS without NRI Growth Rate | 18.3 | |||||
| 3-Year FCF Growth Rate | 16.4 | |||||
| 3-Year Book Growth Rate | -19 | |||||
| Future 3-5Y Total Revenue Growth Rate | 34 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.43 | |||||
| 9-Day RSI | 42.57 | |||||
| 14-Day RSI | 44.44 | |||||
| 6-1 Month Momentum % | 17.54 | |||||
| 12-1 Month Momentum % | -21.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.33 | |||||
| Quick Ratio | 3.32 | |||||
| Cash Ratio | 2.92 | |||||
| Days Inventory | 0.79 | |||||
| Days Sales Outstanding | 78.59 | |||||
| Days Payable | 31.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.6 | |||||
| Shareholder Yield % | -18.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -255.65 | |||||
| Operating Margin % | -557.22 | |||||
| Net Margin % | -568.35 | |||||
| FCF Margin % | -484.35 | |||||
| ROE % | -60.55 | |||||
| ROA % | -52.03 | |||||
| ROIC % | -69.89 | |||||
| ROC (Joel Greenblatt) % | -6805.91 | |||||
| ROCE % | -56.88 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.2 | |||||
| PB Ratio | 3.32 | |||||
| Price-to-Tangible-Book | 13.17 | |||||
| EV-to-EBIT | -5.03 | |||||
| EV-to-Forward-EBIT | -4.74 | |||||
| EV-to-EBITDA | -5.08 | |||||
| EV-to-Forward-EBITDA | -4.74 | |||||
| EV-to-Revenue | 28.18 | |||||
| EV-to-Forward-Revenue | 41.56 | |||||
| EV-to-FCF | -5.66 | |||||
| Price-to-Net-Current-Asset-Value | 13.76 | |||||
| Price-to-Net-Cash | 20.63 | |||||
| Earnings Yield (Greenblatt) % | -19.9 | |||||
| FCF Yield % | -15.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egetis Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 57.5 | ||
| EPS (TTM) (kr) | -1.2 | ||
| Beta | 0.13 | ||
| Volatility % | 55.13 | ||
| 14-Day RSI | 44.44 | ||
| 14-Day ATR (kr) | 0.336744 | ||
| 20-Day SMA (kr) | 6.525 | ||
| 12-1 Month Momentum % | -21.78 | ||
| 52-Week Range (kr) | 3.8 - 9.2 | ||
| Shares Outstanding (Mil) | 292.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egetis Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egetis Therapeutics AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Egetis Therapeutics AB Frequently Asked Questions
What is Egetis Therapeutics AB(OSTO:EGTX)'s stock price today?
The current price of OSTO:EGTX is kr6.19. The 52 week high of OSTO:EGTX is kr9.20 and 52 week low is kr3.80.
When is next earnings date of Egetis Therapeutics AB(OSTO:EGTX)?
The next earnings date of Egetis Therapeutics AB(OSTO:EGTX) is 2024-05-03.
Does Egetis Therapeutics AB(OSTO:EGTX) pay dividends? If so, how much?
Egetis Therapeutics AB(OSTO:EGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers